NSE / BSEHealthcare
β‚Ή957.45-8.40-0.87%
P/E51.8Mkt Capβ‚Ή3.94 K CrEV/EBITDA34.2

INNOVA CAPTAB LIMITED

P/E51.8Mkt Capβ‚Ή3.94 K CrEV/EBITDA34.2
Company Profile

Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and heparin NSAIDs, analgesics and antipyretic, anticold and antiallergic, antiemetic, antidiabetic, antispasmodic, antifibrinolytic, cardiovascular, antioxidant and vitamins, antihyperuricemia and antigout, fluoroquinolone and macrolide, nootropics and neurotonics/neurotrophics, antiulcerative, antimalarial anxiolytic, anticonvulsant and antipsychotic, bladder and prostate disorder, antifungal, anthelmintic and antiviral, anticholinergic, anti-asthmatic, and bronchodilator products in the form of tablets, capsules, dry syrups, dry powder injection, ointments, and liquid orals. The company sells its branded generic products through a network of distributors and pharmacies, as well as online channels in various e-commerce pharmacy sites. Innova Captab Limited was incorporated in 2005 and is based in Panchkula, India.

Valuation

Market Cap
β‚Ή0.00
β€”
Current Price
β‚Ή0
β€”as of 28 Jul 2026
P/E Ratio
0.0x
β€”
P/B Ratio
0.0x
β€”
EV / EBITDA
0.0x
β€”
EV / Sales
0.0x
β€”
52W High
β‚Ή0
β€”
52W Low
β‚Ή0
β€”
Shares Out
0.00 Cr
β€”

Profitability

Operating Margin
0.0%
β€”
Net Profit Margin
0.0%
β€”
EBITDA Margin
0.0%
β€”

Returns

ROE
0.0%
β€”
ROCE
0.0%
β€”
ROIC %
β€”
β€”
ROA
0.0%
β€”
Dividend Payout
0.0%
β€”

Solvency

Current Ratio
0.0x
β€”
Debt / Equity
0.0x
β€”
Debt / Assets
0.0x
β€”
CFO / Net Profit
0.0x
β€”
Interest Coverage
0.0x
β€”

AI Summary

Indian Stock

Sign up free to view AI insights

Get Started

Rule-based from financial data. Not advice.

Price Historyβ–² 9.11% over 1Y
Monthly Returns

Historically, Jul has averaged the highest return (+9.4%); Feb the lowest (-9.6%).

Average from:
YearJanFebMarAprMayJunJulAugSepOctNovDec
2026-3.2%Negative MonthJan 2026: -3.19%-3.6%Negative MonthFeb 2026: -3.62%+2.8%Positive MonthMar 2026: +2.78%+9.3%Positive MonthApr 2026: +9.27%+12.9%Positive MonthMay 2026: +12.93%+15.2%Positive MonthJun 2026: +15.22%-2.0%*Negative MonthJul 2026: -2.03%β€”β€”β€”β€”β€”
2025-10.2%Negative MonthJan 2025: -10.19%-27.6%Negative MonthFeb 2025: -27.62%+20.8%Positive MonthMar 2025: +20.76%+0.8%Neutral MonthApr 2025: +0.76%-0.9%Neutral MonthMay 2025: -0.86%-2.1%Negative MonthJun 2025: -2.06%+5.9%Positive MonthJul 2025: +5.92%-0.9%Neutral MonthAug 2025: -0.94%-5.4%Negative MonthSep 2025: -5.36%-2.4%Negative MonthOct 2025: -2.42%-13.6%Negative MonthNov 2025: -13.59%-0.3%Neutral MonthDec 2025: -0.27%
2024-5.3%Negative MonthJan 2024: -5.28%+2.4%Positive MonthFeb 2024: +2.35%-15.2%Negative MonthMar 2024: -15.20%+5.5%Positive MonthApr 2024: +5.51%+1.4%Neutral MonthMay 2024: +1.45%+5.9%Positive MonthJun 2024: +5.92%+24.3%Positive MonthJul 2024: +24.26%+4.3%Positive MonthAug 2024: +4.26%+17.3%Positive MonthSep 2024: +17.33%+1.0%Neutral MonthOct 2024: +1.03%+31.0%Positive MonthNov 2024: +30.99%+9.4%Positive MonthDec 2024: +9.36%
2023β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”β€”
AvgΒ±SD-6.2%Β±2.9%-9.6%Β±13.0%+2.8%Β±14.7%+5.2%Β±3.5%+4.5%Β±6.0%+6.4%Β±7.1%+9.4%Β±11.0%+1.7%Β±2.6%+6.0%Β±11.3%-0.7%Β±1.7%+8.7%Β±22.3%+4.5%Β±4.8%
* Current month β€” value will change until month-end.

Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation β€” the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.

Seasonal Tendency

This aggregates every month by calendar position β€” all Januaries together, all Februaries together, and so on β€” to show whether a given month has leaned positive or negative historically. β€˜Simple’ counts each month as +1 or βˆ’1. β€˜Weighted’ gives larger moves more influence: +2 above +10%, βˆ’2 below βˆ’10%. With only 4 years of history for this asset, each month’s score reflects a small number of observations β€” read it as a historical tendency, not a reliable seasonal pattern.

Historical Trend

This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.

Year-to-Date ROI
Average from:
SD Γ—
Latest: 1.336x (2026)

Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen β€” at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in β€œAverage from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.

Historical Performance

Revenue, profitability, and cash flow trends (β‚Ή Crores)

Revenue (10Y)

Operating Income (10Y)

Net Profit (10Y)

Operating Margin % (10Y)

Dividend Payout % (10Y)

Free Cash Flow (10Y)

Growth Summary

Latest fiscal year: Mar 2025

Revenueβ‚Ή958.00 Crβ–² 10.8%
EBITDA Growthβ€”
Net Profitβ‚Ή89.00 Crβ–² 30.9%
Cash from Ops (CFO)β€”
Free Cash Flow (FCF)β€”β–Ό 50.0%
Revenue CAGR 5Y18.3%
EBITDA CAGR 5Y18.0%
Net Profit CAGR 5Y19.4%
NP Growth 1Y30.9%

Historical Growth

Year-by-year revenue, profitability, and cash flow (β‚Ή Crores, last 10 years)

YearRevenueOp. IncomeNet ProfitCFOFCFROERev Growth 1YNP Growth 1Y
Mar 2025β‚Ή958.00 Crβ€”β‚Ή89.00 Crβ€”β€”10.9%10.8%30.9%
Mar 2024β‚Ή865.00 Crβ€”β‚Ή68.00 Crβ€”β€”9.4%0.7%17.2%
Mar 2023β‚Ή859.00 Crβ€”β‚Ή58.00 Crβ€”β€”21.6%9.4%-12.1%
Mar 2022β‚Ή785.00 Crβ€”β‚Ή66.00 Crβ€”β€”31.3%91.0%94.1%
Mar 2021β‚Ή411.00 Crβ€”β‚Ή34.00 Crβ€”β€”23.4%10.2%21.4%
Mar 2020β‚Ή373.00 Crβ€”β‚Ή28.00 Crβ€”β€”25.5%β€”β€”

Financial Statements

Income statement, balance sheet, and cash flow (β‚Ή Crores, as reported)

Consolidated Figures in USD Millions.

Unnamed: 0Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025TTM
Revenue / Net Sales3734117858598659581,068
Total Expenses322356687760755836943
EBIT / Operating Profit51549999110122125
OPM %14%13%13%11%13%13%12%
Other Income113991717
Finance Costs5451814210
Depreciation & Amortisation106711111729
Profit Before Tax3846897894120102
Tax %26%26%25%26%27%25%-
Net Profit / PAT28346658688976
EPS (β‚Ή)232.42287.50551.5011.9911.9115.6313.30
Dividend Payout %0%0%0%0%0%0%-

Peer Comparison

Healthcare sector peers, ranked by market cap

CompanyMarket CapRevenueP/EP/BEV/EBITDARev G 1Y
INNOVA CAPTAB LIMITEDthis co.β‚Ή3.94 K Crβ‚Ή958.00 Cr51.804.6534.2110.8%
Sun Pharmaceutical Industries Ltd.β‚Ή4.15 L Crβ‚Ή23.00 K Cr88.7017.4372.3013.5%
Divi's Laboratories Ltd.β‚Ή1.71 L Crβ‚Ή9.20 K Cr67.9011.1367.2120.0%
Torrent Pharmaceuticals Ltd.β‚Ή1.33 L Crβ‚Ή9.68 K Cr62.5015.7645.6413.5%
Cipla Ltd.β‚Ή1.17 L Crβ‚Ή19.05 K Cr22.503.5119.3314.9%
Apollo Hospitals Enterprises Ltd.β‚Ή1.05 L Crβ‚Ή8.20 K Cr75.0011.2854.4412.8%
Max Healthcare Institute Limitedβ‚Ή1.00 L Crβ‚Ή2.66 K Cr144.0011.7696.8413.8%
Industry Averageβ€”β‚Ή3.29 K Cr98.638.1165.5020.2%

Learn while you research

Hand-picked academy chapters to deepen your understanding of INNOVA CAPTAB LIMITED and the metrics that matter.

Browse the full Equiscale Academy